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OBJECTIVES: Everolimus and sunitinib are indicated to treat patients with 
advanced, progressive pancreatic neuroendocrine tumors (pNETs). This analysis 
examines the projected cost-effectiveness of everolimus versus sunitinib in this 
setting from a Swedish payer’s perspective. METHODS: A lifetime Markov model 
was developed to simulate a cohort of advanced, progressive pNET patients to 
estimate the incremental cost-effectiveness when treating with everolimus (10 
mg/day) versus sunitinib (37.5 mg/day). Efficacy inputs were based on a weight-
adjusted indirect comparison of the therapies using the respective phase 3 trial 
data (Signorovitch et al. 2013 and data on file). The disease pathway is reflected 
through mutually exclusive health states: stable disease without adverse events, 
stable disease with adverse events, disease progression, and death. Unit costs 
were obtained from public official Swedish sources. The model includes only 
direct costs. Resource use was based on a German physician survey, validated 
and adapted to Swedish conditions. Costs were represented in 2014 Swedish Krona 
(SEK). The incremental cost-effectiveness ratio (ICER) was calculated. Two-way 
sensitivity analyses were conducted to test the model’s robustness. RESULTS: 
In the base case, the estimated gain of everolimus over sunitinib was 0.357 LYs 
(0.261 QALYs), which results in an ICER that ranges from 100,000 -200,000 SEK/
QALY depending on the assumptions around the duration of therapy for active 
treatment. The analysis is sensitive to the uncertainty of the indirect analysis 
results and variables such as dose intensity. CONCLUSIONS: This model, based 
on an indirect comparison of phase 3 studies, indicates that everolimus is cost-
effective relative to sunitinib in advanced pNET. Its reliance on an indirect analysis 
due to the lack of head-to-head randomized controlled trial data warrants future 
research; however, model results indicate that everolimus is a valuable treatment 
option for pNET patients in Sweden.
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OBJECTIVES: The aim of the study was to analyze the cost-effectiveness of 
cetuximab compared to bevacizumab, both in combination with cytotoxic 
chemotherapy (folinic acid, fluorouracil and irinotecan, FOLFIRI), for first-line 
treatment of RAS wild-type metastatic colorectal cancer, under the public per-
spective in Brazil. METHODS: A cost-effectiveness analysis has been developed 
based on a Markov model, comparing the use of cetuximab+FOLFIRI versus 
bevacizumab+FOLFIRI. Only 2014 direct medical costs were considered in the 
analyses and outcomes were measured in terms of life years saved. Efficacy 
data were obtained from the recently published clinical trial FIRE-3, a head-
to-head trial between cetuximab+FOLFIRI and Bevacizumab+FOLFIRI, and 
costs were obtained from national databases, reflecting the perspective of the 
public healthcare sector in Brazil as a third party payer. Costs and outcomes 
were discounted to present value at a 5% annual rate. The time horizon con-
sidered 10 years. The total number of patients was calculated by the number 
of patients currently receiving chemotherapy who would be considered RAS 
wild-type and eligible to use cetuximab. RESULTS: In a 10 years time horizon, 
the use of cetuximab + FOLFIRI achieved clinical gains of 0,51 life years saved 
compared to bevacizumab + FOLFIRI, with an average cost reduction of R$1,953 
per patient. Cetuximab was shown to be a dominant therapy compared to bev-
acizumab, saving resources up to BRL 14,450,940.00 considering 5,171 patients 
in 2015. CONCLUSIONS: The use of cetuximab as first-line treatment for wild-
type RAS metastatic colorectal cancer has shown significant and clinically 
meaningful benefits while being cost-saving to the Brazilian public healthcare 
system.
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OBJECTIVES: Population-wide screening for epidermal growth factor receptor (EGFR) 
mutations and anaplastic lymphoma kinase (ALK) gene rearrangements to inform 
cancer therapy in non-small cell lung cancer (NSCLC) is recommended by guidelines. 
We estimated cost-effectiveness of multiplexed predictive biomarker screening in 
metastatic NSCLC from a societal perspective in the US. METHODS: We constructed 
a microsimulation model to compare the life expectancy and costs of multiplexed 
testing and molecularly guided therapy vs treatment with cisplatin-pemetrexed 
(CisPem). All testing interventions included a two-step algorithm of concurrent 
EGFR mutation and ALK overexpression testing with immunohistochemistry (IHC) 
followed by ALK rearrangement confirmation with a fluorescence in situ hybridiza-
tion (FISH) assay for IHC positive results. Three strategies were included: ‘Test-treat’ 
approach, where molecularly guided therapy was initiated after obtainment of test 
results; ‘Empiric switch therapy’, with concurrent initiation of CisPem and testing 
and immediate switch to test-result conditional treatment after one cycle of CisPem; 
and ‘Empiric therapy’ approach in which CisPem was continued for four cycles before 
start of a tyrosine kinase inhibitor (TKI). RESULTS: The incremental cost-effective-
ness ratio (ICER) for ‘Test-treat’ compared to treatment with CisPem was $136,000 
per quality-adjusted life year (QALY) gained. Both empiric treatment approaches 
had less favorable ICERs. ‘Test-treat’ and ‘Empiric switch therapy’ yielded higher 
expected outcomes in terms of QALYs and life-years (LYs) than ‘Empiric therapy’. 
These results were robust across plausible ranges of model inputs. CONCLUSIONS: 
From a societal perspective, our cost-effectiveness results support the value 
of multiplexed genetic screening and molecularly guided therapy in metastatic 
NSCLC.
and pharmacoeconomic analysis results were validated by probabilistic sensitiv-
ity analysis. CONCLUSIONS: Sorafenib is cost-effective for treatment of patients 
with RAI refractory locally advanced/metastatic DTC compared to BSC with an 
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OBJECTIVES: To evaluate the cost-effectiveness of primary prophylaxis (PP) with 
pegfilgrastim vs lipegfilgrastim to reduce the incidence of febrile neutropenia (FN) 
in patients with stage II breast cancer receiving 4-cycle TC (docetaxel, cyclophos-
phamide) and patients with non-Hodgkin lymphoma receiving 6-cycle R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) over a life-
time horizon from a Belgian payer perspective. METHODS: A Markov cycle tree 
model tracks FN events during chemotherapy (3-week cycles) and long-term sur-
vival (1-year cycles). Model inputs include: the odds ratio of FN between lipegfil-
grastim PP and pegfilgrastim PP (median [95% credible interval]: 1.39 [0.54–3.50]), 
estimated from a meta-analysis of randomized controlled trials using mixed-
treatment comparison; equivalent prices of lipegfilgrastim and pegfilgrastim since 
the launch of lipegfilgrastim in Belgium (August 2014); mortality (which is affected 
by FN and chemotherapy relative dose intensity); costs (in 2014 € ); and utilities. 
All inputs were estimated from public sources, research databases, and peer-
reviewed publications. Quality-adjusted life-years (QALYs) and expected lifetime 
costs were estimated for each strategy. Probabilistic sensitivity analyses (PSA) 
and scenario analyses were conducted. RESULTS: Pegfilgrastim PP dominated 
lipegfilgrastim PP, with total lifetime costs of € 7,482 vs € 7,806 for TC and € 19,149 
vs € 19,801 for R-CHOP and total lifetime QALYs of 13.379 vs 13.348 for TC and 
4.241 vs 4.184 for R-CHOP. At a willingness-to-pay threshold of € 30,000 per QALY, 
pegfilgrastim PP was cost-effective vs lipegfilgrastim PP in approximately 75% of 
PSA simulations for both regimens. In a scenario analysis when the lipegfilgrastim 
price was set at 90% that of pegfilgrastim, the incremental cost-effectiveness 
ratios for pegfilgrastim PP vs lipegfilgrastim PP were € 4,700 per QALY gained for 
TC and € 857 per QALY gained for R-CHOP. CONCLUSIONS: From a Belgian payer 
perspective, pegfilgrastim PP is cost-effective vs lipegfilgrastim PP in patients with 
stage II breast cancer receiving TC and in patients with non-Hodgkin lymphoma 
receiving R-CHOP.
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